Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.72 EUR | +1.78% |
|
-1.04% | -36.76% |
Apr. 30 | Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 15 | Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development | MT |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 3.049 | 0.5368 | 2.684 | 7.754 | 5.103 | 9.013 |
Enterprise Value (EV) 1 | 5.251 | 3.264 | 5.311 | 7.268 | 4.682 | 8.379 |
P/E ratio | -0.52 x | -0.14 x | 16.7 x | 4.78 x | 14 x | 3.28 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.74 x | 0.33 x | 1.55 x | 4.02 x | 2.69 x | 1.77 x |
EV / Revenue | 1.28 x | 2 x | 3.06 x | 3.77 x | 2.47 x | 1.65 x |
EV / EBITDA | -4.89 x | -10.2 x | 19.2 x | 18.6 x | 9.26 x | 18.4 x |
EV / FCF | -1.67 x | 8.34 x | -1.74 x | -1.67 x | 44.1 x | -4.15 x |
FCF Yield | -59.8% | 12% | -57.5% | -59.8% | 2.27% | -24.1% |
Price to Book | 6.5 x | -0.16 x | -0.84 x | -4.91 x | -4.24 x | 5.82 x |
Nbr of stocks (in thousands) | 3,314 | 3,314 | 3,314 | 3,314 | 3,314 | 3,314 |
Reference price 2 | 0.9200 | 0.1620 | 0.8100 | 2.340 | 1.540 | 2.720 |
Announcement Date | 4/30/19 | 6/2/20 | 5/21/21 | 4/29/22 | 4/27/23 | 4/30/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 4.111 | 1.634 | 1.736 | 1.929 | 1.896 | 5.088 |
EBITDA 1 | -1.075 | -0.3206 | 0.2771 | 0.3916 | 0.5059 | 0.4544 |
EBIT 1 | -1.324 | -0.4672 | 0.2051 | 0.282 | 0.3708 | 0.3194 |
Operating Margin | -32.2% | -28.59% | 11.81% | 14.61% | 19.56% | 6.28% |
Earnings before Tax (EBT) 1 | -5.695 | -3.462 | 0.1696 | 0.3403 | 0.3657 | 3.729 |
Net income 1 | -5.811 | -3.834 | 0.1609 | 1.622 | 0.3767 | 2.751 |
Net margin | -141.36% | -234.58% | 9.27% | 84.09% | 19.87% | 54.07% |
EPS 2 | -1.754 | -1.160 | 0.0486 | 0.4896 | 0.1100 | 0.8300 |
Free Cash Flow 1 | -3.138 | 0.3914 | -3.055 | -4.347 | 0.106 | -2.02 |
FCF margin | -76.34% | 23.95% | -176% | -225.29% | 5.59% | -39.7% |
FCF Conversion (EBITDA) | - | - | - | - | 20.96% | - |
FCF Conversion (Net income) | - | - | - | - | 28.15% | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/30/19 | 6/2/20 | 5/21/21 | 4/29/22 | 4/27/23 | 4/30/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 2.2 | 2.73 | 2.63 | - | - | - |
Net Cash position 1 | - | - | - | 0.49 | 0.42 | 0.63 |
Leverage (Debt/EBITDA) | -2.049 x | -8.505 x | 9.483 x | - | - | - |
Free Cash Flow 1 | -3.14 | 0.39 | -3.05 | -4.35 | 0.11 | -2.02 |
ROE (net income / shareholders' equity) | -172% | 265% | -4.9% | -67.8% | -27.1% | 1,618% |
ROA (Net income/ Total Assets) | -6.83% | -4.53% | 2.76% | 3.25% | 3.86% | 2.77% |
Assets 1 | 85.12 | 84.62 | 5.826 | 50 | 9.762 | 99.2 |
Book Value Per Share 2 | 0.1400 | -1.020 | -0.9700 | -0.4800 | -0.3600 | 0.4700 |
Cash Flow per Share 2 | 0.2700 | 0.1300 | 0.1700 | 0.1500 | 0.1300 | 0.2200 |
Capex 1 | 0.18 | 0.2 | 0.21 | 0.35 | 0.28 | 0.3 |
Capex / Sales | 4.45% | 12.44% | 11.88% | 18.29% | 14.63% | 5.81% |
Announcement Date | 4/30/19 | 6/2/20 | 5/21/21 | 4/29/22 | 4/27/23 | 4/30/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-36.76% | 6.05M | |
-12.87% | 192B | |
+6.25% | 172B | |
+7.45% | 161B | |
+1.69% | 96.97B | |
+51.64% | 94.22B | |
+15.11% | 84.86B | |
+7.37% | 80.73B | |
+4.36% | 48.04B | |
-28.21% | 47.84B |
- Stock Market
- Equities
- ALKLA Stock
- Financials Klarsen